|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPP1R10 |
Gene summary for PPP1R10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPP1R10 | Gene ID | 5514 |
| Gene name | protein phosphatase 1 regulatory subunit 10 | |
| Gene Alias | CAT53 | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q2L6I0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5514 | PPP1R10 | AEH-subject1 | Human | Endometrium | AEH | 1.50e-29 | 5.66e-01 | -0.3059 |
| 5514 | PPP1R10 | AEH-subject2 | Human | Endometrium | AEH | 2.06e-05 | 2.42e-01 | -0.2525 |
| 5514 | PPP1R10 | AEH-subject3 | Human | Endometrium | AEH | 2.46e-07 | 2.72e-01 | -0.2576 |
| 5514 | PPP1R10 | AEH-subject4 | Human | Endometrium | AEH | 6.11e-03 | 1.89e-01 | -0.2657 |
| 5514 | PPP1R10 | EEC-subject1 | Human | Endometrium | EEC | 9.04e-05 | 2.18e-01 | -0.2682 |
| 5514 | PPP1R10 | EEC-subject3 | Human | Endometrium | EEC | 2.17e-08 | -6.64e-02 | -0.2525 |
| 5514 | PPP1R10 | EEC-subject4 | Human | Endometrium | EEC | 7.27e-04 | 1.91e-01 | -0.2571 |
| 5514 | PPP1R10 | GSM5276934 | Human | Endometrium | EEC | 7.25e-21 | 5.61e-01 | -0.0913 |
| 5514 | PPP1R10 | GSM5276937 | Human | Endometrium | EEC | 2.95e-13 | 4.91e-01 | -0.0897 |
| 5514 | PPP1R10 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.86e-12 | -3.58e-01 | -0.1869 |
| 5514 | PPP1R10 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.31e-13 | -4.09e-01 | -0.1875 |
| 5514 | PPP1R10 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 7.34e-13 | -3.66e-01 | -0.1883 |
| 5514 | PPP1R10 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.11e-18 | -2.31e-01 | -0.1934 |
| 5514 | PPP1R10 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.12e-23 | -2.23e-01 | -0.1917 |
| 5514 | PPP1R10 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 3.85e-21 | -1.34e-01 | -0.1916 |
| 5514 | PPP1R10 | LZE2D | Human | Esophagus | HGIN | 4.26e-02 | 7.52e-02 | 0.0642 |
| 5514 | PPP1R10 | LZE4T | Human | Esophagus | ESCC | 1.32e-12 | 5.96e-01 | 0.0811 |
| 5514 | PPP1R10 | LZE5T | Human | Esophagus | ESCC | 6.93e-07 | 4.48e-01 | 0.0514 |
| 5514 | PPP1R10 | LZE7T | Human | Esophagus | ESCC | 1.15e-07 | 7.94e-01 | 0.0667 |
| 5514 | PPP1R10 | LZE8T | Human | Esophagus | ESCC | 1.31e-08 | 5.57e-01 | 0.067 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000734610 | Esophagus | HGIN | regulation of mitotic cell cycle | 98/2587 | 457/18723 | 4.39e-06 | 1.42e-04 | 98 |
| GO:003220416 | Esophagus | HGIN | regulation of telomere maintenance | 27/2587 | 80/18723 | 4.83e-06 | 1.56e-04 | 27 |
| GO:003220617 | Esophagus | HGIN | positive regulation of telomere maintenance | 20/2587 | 52/18723 | 8.82e-06 | 2.64e-04 | 20 |
| GO:005105214 | Esophagus | HGIN | regulation of DNA metabolic process | 79/2587 | 359/18723 | 1.38e-05 | 3.85e-04 | 79 |
| GO:001703817 | Esophagus | HGIN | protein import | 51/2587 | 206/18723 | 1.79e-05 | 4.86e-04 | 51 |
| GO:005117010 | Esophagus | HGIN | import into nucleus | 41/2587 | 159/18723 | 4.24e-05 | 1.04e-03 | 41 |
| GO:200102019 | Esophagus | HGIN | regulation of response to DNA damage stimulus | 52/2587 | 219/18723 | 5.00e-05 | 1.19e-03 | 52 |
| GO:000660610 | Esophagus | HGIN | protein import into nucleus | 39/2587 | 155/18723 | 1.14e-04 | 2.39e-03 | 39 |
| GO:005105416 | Esophagus | HGIN | positive regulation of DNA metabolic process | 47/2587 | 201/18723 | 1.65e-04 | 3.21e-03 | 47 |
| GO:00322007 | Esophagus | HGIN | telomere organization | 38/2587 | 159/18723 | 4.23e-04 | 6.39e-03 | 38 |
| GO:00427708 | Esophagus | HGIN | signal transduction in response to DNA damage | 39/2587 | 172/18723 | 1.07e-03 | 1.32e-02 | 39 |
| GO:00459305 | Esophagus | HGIN | negative regulation of mitotic cell cycle | 49/2587 | 235/18723 | 1.88e-03 | 2.01e-02 | 49 |
| GO:004593110 | Esophagus | HGIN | positive regulation of mitotic cell cycle | 28/2587 | 121/18723 | 3.72e-03 | 3.39e-02 | 28 |
| GO:19019876 | Esophagus | HGIN | regulation of cell cycle phase transition | 72/2587 | 390/18723 | 5.78e-03 | 4.70e-02 | 72 |
| GO:00447735 | Esophagus | HGIN | mitotic DNA damage checkpoint | 20/2587 | 81/18723 | 6.16e-03 | 4.92e-02 | 20 |
| GO:20010214 | Esophagus | HGIN | negative regulation of response to DNA damage stimulus | 20/2587 | 81/18723 | 6.16e-03 | 4.92e-02 | 20 |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006913110 | Esophagus | ESCC | nucleocytoplasmic transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:0051169110 | Esophagus | ESCC | nuclear transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
| GO:003450418 | Esophagus | ESCC | protein localization to nucleus | 211/8552 | 290/18723 | 4.06e-21 | 6.60e-19 | 211 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPP1R10 | SNV | Missense_Mutation | novel | c.2333N>A | p.Gly778Glu | p.G778E | Q96QC0 | protein_coding | tolerated_low_confidence(0.06) | benign(0.017) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| PPP1R10 | SNV | Missense_Mutation | novel | c.1669G>A | p.Val557Ile | p.V557I | Q96QC0 | protein_coding | tolerated(0.21) | probably_damaging(0.967) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| PPP1R10 | SNV | Missense_Mutation | novel | c.2368N>C | p.Ser790Arg | p.S790R | Q96QC0 | protein_coding | tolerated_low_confidence(0.1) | benign(0.003) | TCGA-LL-A5YN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| PPP1R10 | insertion | Frame_Shift_Ins | novel | c.1483_1484insT | p.Gln495LeufsTer12 | p.Q495Lfs*12 | Q96QC0 | protein_coding | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | ||
| PPP1R10 | insertion | Nonsense_Mutation | novel | c.2107_2108insGAGGTTAGAACTGACTACAAAGACACAGGAA | p.Tyr703Ter | p.Y703* | Q96QC0 | protein_coding | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PPP1R10 | SNV | Missense_Mutation | rs748839668 | c.2764C>T | p.Arg922Cys | p.R922C | Q96QC0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.984) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PPP1R10 | SNV | Missense_Mutation | rs774652564 | c.2345G>A | p.Arg782His | p.R782H | Q96QC0 | protein_coding | deleterious_low_confidence(0.01) | benign(0.12) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PPP1R10 | SNV | Missense_Mutation | rs767544705 | c.1343G>A | p.Arg448Gln | p.R448Q | Q96QC0 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PPP1R10 | SNV | Missense_Mutation | rs747071643 | c.2255N>A | p.Arg752His | p.R752H | Q96QC0 | protein_coding | tolerated_low_confidence(0.08) | benign(0.057) | TCGA-DR-A0ZL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PPP1R10 | SNV | Missense_Mutation | novel | c.249N>C | p.Lys83Asn | p.K83N | Q96QC0 | protein_coding | deleterious(0.02) | possibly_damaging(0.863) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |